Key Points
- Natera director Gail Boxer Marcus sold 11,000 shares on June 5 at an average price of $217.21, generating about $2.39 million in proceeds.
- After the sale, Marcus directly owned 6,183 shares, a 64.02% decrease in her position. The trade was disclosed in an SEC filing.
- Natera shares were up 4.4% and opened at $222.82, while analysts maintain a Moderate Buy consensus with an average price target of $256.12.
Natera, Inc. (NASDAQ:NTRA - Get Free Report) Director Gail Boxer Marcus sold 11,000 shares of the firm's stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $217.21, for a total transaction of $2,389,310.00. Following the sale, the director directly owned 6,183 shares of the company's stock, valued at approximately $1,343,009.43. This trade represents a 64.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Natera Stock Up 4.4%
Shares of NTRA stock opened at $222.82 on Wednesday. The company has a market cap of $31.91 billion, a price-to-earnings ratio of -136.70 and a beta of 1.56. Natera, Inc. has a 52 week low of $131.81 and a 52 week high of $256.36. The firm has a 50 day moving average of $205.34 and a 200-day moving average of $216.16.
Institutional Trading of Natera
Hedge funds have recently bought and sold shares of the business. Robinhood Asset Management LLC acquired a new stake in Natera in the 4th quarter valued at $12,981,000. JPMorgan Chase & Co. lifted its stake in Natera by 9.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company's stock valued at $1,871,914,000 after acquiring an additional 1,003,129 shares in the last quarter. Krilogy Financial LLC bought a new position in Natera during the 3rd quarter valued at $1,323,000. Zweig DiMenna Associates LLC lifted its stake in Natera by 6.8% during the 3rd quarter. Zweig DiMenna Associates LLC now owns 132,500 shares of the medical research company's stock valued at $21,329,000 after acquiring an additional 8,400 shares in the last quarter. Finally, Systrade AG bought a new position in Natera during the 4th quarter valued at $11,454,000. Institutional investors and hedge funds own 99.90% of the company's stock.
Analyst Upgrades and Downgrades
Several analysts have recently commented on NTRA shares. BTIG Research reduced their price objective on shares of Natera from $260.00 to $250.00 and set a "buy" rating for the company in a research report on Monday, May 11th. Wolfe Research started coverage on shares of Natera in a research report on Tuesday, June 2nd. They set an "outperform" rating and a $260.00 price objective for the company. Wells Fargo & Company raised their price objective on shares of Natera from $215.00 to $220.00 and gave the stock an "equal weight" rating in a research report on Friday, May 8th. Wall Street Zen downgraded shares of Natera from a "buy" rating to a "hold" rating in a research report on Saturday, May 9th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Natera from $260.00 to $265.00 and gave the company an "overweight" rating in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Natera currently has a consensus rating of "Moderate Buy" and an average target price of $256.12.
Read Our Latest Stock Analysis on Natera
Natera Company Profile
(
Get Free Report)
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
